Applications of 5-(2-Furyl)Isoxazole-3-Carboxylic Acid in Industrial Manufacturing

5-(2-Furyl)Isoxazole-3-carboxylic acid serves as a key intermediate compound across several high-value industrial sectors. As the original manufacturer, we support leading enterprises in precisely formulated syntheses and strictly controlled process environments. The following overview details verified application channels, aligned with regulatory standards and specific process methodologies.

1. Active Pharmaceutical Ingredient (API) Intermediate for Antimicrobial Drug Synthesis

Pharmaceutical companies utilize this intermediate in preparative steps for specialty antimicrobial APIs. Stringent process validation ensures consistent heterocyclic framework construction in commercial batch scales. Our technical collaboration with API manufacturers focuses on molecular purity, consistent crystallization, and impurity profile management across continuous and batch process lines.

Industry compliance standards

• ICH Q7 GMP Guidelines for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals)
• Ph. Eur. Monograph 5.1 on Intermediates and Starting Substances
• Chinese Pharmacopoeia raw material testing requirements

Typical usage ratio

• Used at 0.8–1.2 molar equivalents relative to the coupling partner, precisely adjusted depending on the downstream target molecule and multi-step synthesis needs

Downstream process integration

• Introduced during the key cyclization or condensation step after preliminary substrate protection and activation
• Subsequent intermediate purification performed via crystallization or column chromatography, prior to final API assembly

Final product types

• Semi-synthetic antimicrobial oral solid dosage forms (tablets, capsules)
• Injectable antimicrobials
• Topical antimicrobial creams and ointments

2. Heterocyclic Building Block for Agrochemical Active Ingredient Synthesis

Manufacturers of crop protection formulations use this compound as a core building block in the construction of isoxazole-derived herbicidal and fungicidal agents. The material’s functional group configuration supports direct integration into patented actives, enabling reliable batch-scale production and stringent residue control for regulated markets.

Industry compliance standards

• FAO/WHO Specification for Pesticide Technical Grade Active Ingredients (FAO/WHO/TGAs)
• ISO 16140:2016 for Analytical Quality and Traceability
• China GB 2763–2021 Maximum Residue Limits for Pesticides in Food
• European Regulation (EC) No 1107/2009

Typical usage ratio

• Dosage per batch: 2–5% w/w within the technical concentrate, varying according to the synthesis route for each active compound

Downstream process integration

• Added during the heteroaromatic coupling stage of active ingredient synthesis, directly preceding oxidation or halogenation reactions
• Process controls focus on temperature gradients and byproduct minimization

Final product types

• Technical grade herbicides
• Emulsifiable concentrate and suspension concentrate fungicide products
• Pre-mix granule crop-protection agents

3. Specialty Intermediate for Veterinary Drug Formulations

Animal health manufacturers integrate this compound in the assembly of selective veterinary active molecules with isoxazole skeletons. Synthesis protocol emphasizes process safety, impurity tracking, and selective functionalization to ensure compatibility with livestock and companion animal use.

Industry compliance standards

• US FDA Center for Veterinary Medicine (CVM) Guidance for Industry (GFI) #61
• VICH GL10 Stability Testing for New Veterinary Drug Substances
• European Pharmacopoeia monographs for veterinary actives
• ISO 9001:2015 for quality management of APIs and intermediates

Typical usage ratio

• Formulation: 1.5–3.5% by weight as an intermediate in multi-component veterinary active assembly, tailored to molecular target and yield requirements

Downstream process integration

• Loaded into the initial cyclization step or intermediate modification phase
• Pigment removal and impurity stripping performed pre-final active crystallization

Final product types

• Veterinary oral suspensions
• Therapeutic injectable preparations for livestock
• Topical veterinary solutions

4. Intermediate for Specialty Fine Chemicals and Electronic Chemical Synthesis

Leading manufacturers of electronic chemicals and specialty fine chemicals apply this molecule in high-purity syntheses for functional materials. Analytical requirements drive batch traceability and impurity profiling for integration into downstream reactions used in semiconductors and specialty coatings.

Industry compliance standards

• SEMI C1-0707 standards for Electronic Chemical Purity 
• ISO 9001:2015 Quality Management System certified electronic grade supply
• RoHS Directive 2011/65/EU (for finished electronics)
• REACH Annex XVII registration requirements (for European Union)

Typical usage ratio

• Purity-specific application: commonly 0.2–1.0% w/w in the feed solution for electronic fine chemical synthesis, based on the precise yield requirements of the end product

Downstream process integration

• Blended during the targeted ring-assembly or esterification steps
• Stringent solvent and purification stages to achieve sub-ppm impurity levels for semiconductor use

Final product types

• Microelectronic coating precursors
• Patterning agents for photoresist chemicals
• Specialty surface treatment agents